We focused on the differences in CEBPA and DNMT3A mutations between AML patients in the Northeast Chinese and Western populations and demonstrated that genetic background differences are important factors affecting the prognostic stratification of AML patients. Here, DNMT3A is linked to acute myeloid leukemia.